Article Figures & Data
Figures
- Figure 1.
Study Design
CrCl=creatinine clearance; EP=end point; ISTH=International Society on Thrombosis and Haemostasis; P-gp=P-glycoprotein; SEE=systemic embolic event.
Reproduced with permission from Elsevier from Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010;160(4):635–641.
- Figure 2.
Primary End Point Analyses
ITT=intention-to-treat; QD=once daily; TTR=time to response.
Reproduced with permission from RP Giugliano, MD.
- Figure 3.
Key Secondary Outcomes
CV=cardiovascular; EP=end point; ICH=intracranial hemorrhage; SEE=systemic embolic event.
Reproduced with permission from RP Giugliano, MD.
Tools
Table of contents
Cited By...
- No citing articles found.